A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors
Trial ID or NCT#
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
- 1. Advanced measurable malignancy 2. Adequate hematologic status 3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1 prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will be considered a systemic therapy. Local radiation and topical agents are not systemic therapies. 4. Adequate coagulation function 5. Adequate hepatic function 6. Adequate renal function
- 1. Known, current central nervous system disease involvement or untreated brain metastases 2. Allogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement 3. History of hemolytic anemia or bleeding diathesis
Contact us to find out if this trial is right for you.
Elle (Hyunjin) Kim
About this Clinical Trial
Your Message Will Go ToElle (Hyunjin) Kim
To:Elle (Hyunjin) Kim
Go Back To The Trial